Banzel (Rufinamide Oral Suspension) and Isavuconazonium Sulfate Injection

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Rufinamide may reduce the blood levels of isavuconazonium. In some cases, this may make the medication less effective. Using rufinamide with isavuconazonium may also increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening, although it is a relatively rare side effect. Talk to your doctor if you have any questions or concerns. Your doctor may already be able to prescribe alternatives that do not interact, or may be aware of the risks but has determined that this is the best course of treatment for you, and is monitoring you closely for any potential complications. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with these medications, whether together or alone. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR: Coadministration with inducers of the CYP450 3A4 isoenzyme may decrease the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT). When multiple doses of isavuconazonium sulfate (prodrug of isavuconazole) were administered to healthy volunteers with multiple doses of the potent CYP450 3A4 inducer rifampin (600 mg), mean isavuconazole peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 75% and 97%, respectively. The extent to which other, less potent inducers of CYP450 3A4 may interact with isavuconazole is unknown. In addition, coadministration with medicines known to decrease the QT interval may increase the arrhythmogenic risk of isavuconazole. Isavuconazole has been shown to shorten the QTc interval. In a QT study in healthy subjects, isavuconazole shortened the QTc interval by a least squares mean of 13.1 milliseconds after a 200 mg dose, and 24.6 milliseconds after a 600 mg dose, measured 2 hours post-dose. However, data are limited on the clinical significance of drug-induced QT-interval shortening. Familial short QT syndrome has been reported to increase the risk for sudden death and ventricular arrhythmias, particularly ventricular fibrillation. Isavuconazole is contraindicated in patients with familial short QT syndrome.

MANAGEMENT: Caution is advised during concomitant use with CYP450 3A4 inducers; the potential for decreased efficacy of isavuconazonium sulfate should be considered. Caution and clinical monitoring should also be considered during concomitant use of isavuconazonium sulfate and medicines known to shorten the QT interval.

Banzel (Rufinamide Oral Suspension)

Generic Name: rufinamide

Brand name: Banzel

Synonyms: Banzel

What is Banzel (Rufinamide Oral Suspension)?

Isavuconazonium Sulfate Injection

Generic Name: isavuconazonium

Brand name: Cresemba

Synonyms: Isavuconazonium, Isavuconazonium Sulfate

What is Isavuconazonium Sulfate Injection?